Get Cash Back and $0 Commissions + The Power of TradeStation
ElectroCore's Truvaga Plus Wins Men's Health Magazine Tech Award
Globe Newswire 12-Nov-2024 4:01 PM
ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been awarded the prestigious Men's Health Magazine Tech Award for a pioneering wellness device recognized for innovation and excellence. The award celebrates groundbreaking advancements in health and technology and highlights products that significantly impact men's health and wellness. A link to the article can be found here: Men'sHealth Tech Awards 2025.
"We are honored to receive the Men's Health Magazine Tech Award for Truvaga Plus," said Dan Goldberger, CEO of ElectroCore. "This recognition underscores our commitment to developing solutions that improve quality of life by managing stress, enhancing sleep, and boosting mental focus. We are proud to have Truvaga Plus earn the recommendation from Men's Health Magazine."
About Men's Health Magazine Men's Health Magazine, published by Hearst, is the world's largest men's magazine brand, offering up-to-date information and advice on every aspect of a man's life, including health, fitness, fashion, and relationships. The magazine reaches a total audience of 21.8 million, including 13.7 million site visitors and 17.2 million social followers accessing trusted content through their digital platforms.
Truvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company's proven technology to quickly and gently activate the vagus nerve. It's designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease.
About electroCore, Inc. electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation ("nVNS") technology platform. The company's is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, new and existing wellness product offerings, new ecommerce site, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including focus group study results; the Company's business prospects in the United States (including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the ability to successfully launch and commercialize Truvaga Plus, the potential impact and effects of COVID-19 on the business of electroCore, electroCore's results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
